Gray N M, Cheng B K, Mick S J, Lair C M, Contreras P C
Central Nervous System Disease Research, G. D. Searle & Co., St. Louis, Missouri 63198.
J Med Chem. 1989 Jun;32(6):1242-8. doi: 10.1021/jm00126a016.
A series of 1,2,3,4-tetrahydroisoquinolines, tetrahydrothieno[2,3-c]pyridines, and related compounds were evaluated for their ability to inhibit binding of [3H]-1-[1-(2-thienyl)piperidine and [3H]-N-allylnormetazocine to phencyclidine (PCP) and sigma receptors, respectively. A representative series of compounds was evaluated in behavioral assays to determine the ability of the compounds to induce PCP-like stereotyped behavior and ataxia. All of the compounds caused stereotyped behavior and ataxia, indicating their agonist actions at the PCP site.